FirstWord

Stenvall will succeed Paul Chaplin, who announced his exit in March after a failed take-private bid.

Laromestrocel failed to significantly improve right ventricular function in a Phase IIb trial of infants with hypoplastic left heart syndrome.

The Phase III EASi-KIDNEY trial was evaluating experimental aldosterone synthase inhibitor vicadrostat (BI 690517) in combination with SGLT2 inhibitor Jardiance in adults with chronic kidney disease.

The Swiss pharma is paying $125 million for the technology, which uses brain delivery modules to transport therapeutics into the brain.

The drug, dubbed VHB937, appears to still be in Phase II testing for early Alzheimer's disease.

FirstWord is hosting an expert call to take stock of how the prescribing landscape for obesity medications is shifting as oral GLP-1s find their footing.

Novo Nordisk — now Novo — is working on a makeover ahead of its sentiment-setting Capital Markets Day presentation next week; FirstWord checks in on what's style and what's substance from the company's new look.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World...

Oxford, UK, September 16, 2026 – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that members of its senior leadership team wil...

PARIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive...